Effectiveness of Manual Acupuncture and Standard Therapy Compared to Standard Therapy in Gynecological Cancer Pain

January 25, 2024 updated by: Suryamin Suryamin, Indonesia University
Cancer patients experience cancer pain as much as 66%. Cancer pain is pain that occurs in patients with neoplastic/malignancy and the source of the pain can come from malignant processes, treatments such as radiotherapy, chemotherapy, and surgery as well as other causes that are not related to malignancy processes. Unresolved pain can reduce the quality and life expectancy of cancer pain patients. The prevalence of cancer itself in Indonesia, the case of cervical cancer itself ranks second after breast cancer. In recent decades, acupuncture analgesics have been widely used to relieve cancer pain, and can also reduce the dose and side effects of analgesics. However, substantially the use of acupuncture in cancer pain is still very rare.

Study Overview

Detailed Description

The main outcome is to analyze the effectiveness of manual acupuncture therapy (LI4,PC6, LR3,ST36, and SP6 plus standard therapy on pain intensity (VAS score), changes in analgesic dose, and quality of life (QLQ C-30 EORTC score) in patients with gynecological cancer pain compared to standard therapy alone.

The patient will attempt 3-day manual acupuncture therapy with seven days follow up Patient will receive acupuncture therapy daily for 3 days, for 15 minute each day.

The research design in this study was a single-blinded randomized control clinical trial. With outcome measures for

With Subject criteria:

Inclusion Criteria

  1. The patient is diagnosed with gynecological cancer
  2. Women over 18 years to 65 years
  3. Subjects experiencing cancer pain, with VAS ≥4, namely pain caused by:

    • tumors,
    • before or during a therapeutic process (radiation therapy, chemotherapy, or post-surgery)
    • side effect or the result of toxicity of cancer treatment
    • Supportive therapy (palliative therapy, painkillers, antidepressants)
  4. Willing to participate in this study and sign an informed consent Exclusion Criteria

1) The patient has a medical emergency / hemodynamically unstable 2) Patients with contraindications for manual acupuncture procedures such as wounds and infections at the point where the puncture will be performed, patients allergic to stainless steel62 3) Uncooperative patients (patients with negative and aggressive affect, who do not allow acupuncture therapy) 4) There is a tumor in the area that will be stabbed and stimulated in the pregnant woman's abdomen, close to the heart, or around the carotid sinus, lymphedema, needle insertion into the prosthesis 5) Patients with heart rhythm disorders 6) The patient uses a pacemaker 7) Patients with disorders of the auricle such as eczema, external otitis, and psoriasis 8) Patients with blood clotting disorders, with platelets <50,000, and in neutropenic conditions with neutrophils <1000

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • DKI Jakarta
      • Jakarta, DKI Jakarta, Indonesia, 14250
        • Suryamin Hung
    • Dki Jakarta
      • Jakarta, Dki Jakarta, Indonesia, 10430
        • Fatmawati Hospital
      • Jakarta, Dki Jakarta, Indonesia, 13230
        • Persahabatan Hospital
      • Jakarta Pusat, Dki Jakarta, Indonesia, 10430
        • Cipto Mangunkusumo Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Female 18 to 65 years old
  • Gynecocal cancer with pain ≥ 4 acording Visual Analog scale and receive analgetic medicine
  • The pain cause by

    1. direct from cancer
    2. Treatment proces surgery, radiotherapy, chemotherapy, paliatif treatment, supportive treatment
    3. Adverse reaction form treatment and intoxication

Exclusion Criteria:

  • emergency case patient with hemodynamic instable
  • patient with uncooperative behavior because ith serious psychological disorders, no currently undergoing psychiatric treatment, aggressive behavior, that not allowed for acupuncture.
  • Patients with blood clotting disorders, with platelets <50.000 and in neutropenic condition with <1000 neutrophils.

The patient has an allergy to stainless steel acupuncture needles. Wounds at the acupuncture point puncture sites, skin infections in the ears. On patients with eczema on the ears, external otitis or psoriasis.

There is a tumor in the area that will be stabbed and stimulated in the stomach pregnant women, close to the heart, or in the area of the carotid sinus lymphedema, insertion into the prosthesis.

Patients with heart rhythm disorders. The patient uses a pace maker.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
The Patient are cancer patient that experience cancer pain that only receive analgetic drug treatment according to WHO Stepledder of Pain
Experimental: Manual acupuncture and standard Therapy
The Patient are cancer patient that experience cancer paint that receive analgetic drug treatement according WHO stepledder of pain and receive manual acupuncture
Acupuncture Needle Insertion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain severity with Visual Analog Scale
Time Frame: Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7
Visual Analog Scale (VAS) that score 0 is no pain to 100 the worse pain A higher scale means worse outcomes
Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life with European Organisation for Research and Treatment of Cancer Quality of Life C30
Time Frame: before treatment and 7 day after treatment
European Organisation for Research and Treatment of Cancer Quality of Life C30, that include two item of review functional scale and the global health scale both scale the higher the score the outcome will be better
before treatment and 7 day after treatment
Analgetic Usage in dosage and frequency
Time Frame: Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7
Description of analagetic dosage and frequency during observation that will be describe as medicine category opioid non opioid, dosage and frequency
Before treatment, After treatment in day 1, day 2, day 3, day 5 and day 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Suryamin Suryamin, Indonesia University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 29, 2023

Primary Completion (Actual)

December 19, 2023

Study Completion (Actual)

December 19, 2023

Study Registration Dates

First Submitted

August 31, 2023

First Submitted That Met QC Criteria

October 4, 2023

First Posted (Actual)

October 6, 2023

Study Record Updates

Last Update Posted (Estimated)

January 29, 2024

Last Update Submitted That Met QC Criteria

January 25, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 23-06-1047

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe